Overview
Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study
Status:
Unknown status
Unknown status
Trial end date:
2020-01-01
2020-01-01
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
To study the impact of mirabegron, a B3-adrenoceptor agonist, in the treatment of ED in patients with LUTS secondary to BPH and concomitant ED.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Mansoura UniversityTreatments:
Mirabegron
Tamsulosin
Criteria
Inclusion Criteria:- Patients with concomitant ED and irritative LUTS secondary to BPH
- Married and sexually motivated.
Exclusion Criteria:
- Men with Peyronie's disease.
- Patients with contraindication to receive mirabegron (High PVR).
- Psychiatric disorders.
- Previous pelvic surgery or trauma
- Men with prostatic adenocarcinoma
- Patients refusing participating in the study